Asset
AZETUKALNER
XENON PHARMACEUTICALS INC. COMMON SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07172516 | phase3 | recruiting | 2025-08-08 | 2028-06-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
| NCT06775379 | phase3 | recruiting | 2024-12-20 | 2026-08-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
| NCT07076407 | phase3 | recruiting | 2025-07-08 | 2027-05-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) |
| NCT05614063 | phase3 | completed | 2022-11-18 | 2026-01-12 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
| NCT05716100 | phase3 | recruiting | 2023-05-09 | 2028-01-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |
FDA applications (0)
This company has no applications containing this asset.